核因子-κB受体激活剂配体-核因子-κB受体激活剂信号传导通路在骨髓瘤骨病中的研究进展  

Receptor Activator of Nuclear Factor κB Ligand-Receptor Activator of Nuclear Factor κB Signaling Pathway in Myeloma Bone Disease

作　　者：冯妍 唐文娇 邹忠晴 崔健 张丽[1] 牛挺[1] FENG Yan;TANG Wenjiao;ZOU Zhongqing;CUI Jian;ZHANG Li;NIU Ting(Institute of Hematology,Department of Hematology,West China Hospital,Sichuan University,Chengdu 610041,China;Department of Hematology,Affiliated Hospital of Chengdu University,Chengdu 610081,China;West China Clinical Medical College,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院血液内科血液病研究所,成都610041 [2]成都大学附属医院血液内科,成都610081 [3]四川大学华西临床医学院,成都610041

出　　处：《中国医学科学院学报》2022年第4期686-692,共7页Acta Academiae Medicinae Sinicae

基　　金：国家自然科学基金(81770218);四川省自然科学基金(2022NSFSC1299)。

摘　　要：多发性骨髓瘤是一种恶性克隆性浆细胞疾病,目前仍无法治愈,约90%多发性骨髓瘤患者在疾病的进程中出现骨髓瘤骨病,严重影响了患者的生活质量和疾病预后。骨髓瘤骨病的传统治疗包括双膦酸盐、放疗、手术治疗等。近年来随着研究证实核因子-κB受体激活剂配体(RANKL)-核因子-κB受体激活剂(RANK)信号传导通路在骨髓瘤骨病中发挥重要作用,为治疗骨髓瘤骨病提供了新靶点。本文就RANKL-RANK信号传导通路在骨髓瘤骨病中的发病机制及靶向治疗新进展进行综述。Multiple myeloma is an incurable malignant disease characterized by proliferation of clonal plasma cells in the bone marrow.About 90% of the patients with multiple myeloma develop myeloma bone disease(MBD),which seriously affects the quality of life and prognosis of the patients.Traditional therapies for MBD include bisphosphonates, radiotherapy, and surgery.The recent studies have confirmed that the receptor activator of nuclear factor κB ligand(RANKL)-receptor activator of nuclear factor κB(RANK) signaling pathway plays a key role in MBD,providing a new therapeutic target for MBD.This review summarized the role of RANKL-RANK signaling pathway in the pathogenesis of MBD and the advance in the targeted therapy.

关 键 词：多发性骨髓瘤 骨髓瘤骨病 核因子-κB受体激活剂配体 

分 类 号：R551.3[医药卫生—血液循环系统疾病]